CDKN2A and astrocytoma (excluding glioblastoma): Given the prognostic role of both CDKN2A/B loss and focal amplifications, we sought to determine whether these two molecular markers could be integrated to refine the histopathologic stratification of IDH1/2-mutant astrocytoma.